Ivzumab - Bevacizumab 400 mg Inj

Ivzumab 400 mg Injection contains bevacizumab, a recombinant monoclonal antibody that targets vascular endothelial growth factor (VEGF). It is primarily used in oncology as part of established treatment protocols for several cancers, including colorectal, lung, kidney, cervical, ovarian, and other malignancies. Bevacizumab is also utilized in specialist ophthalmic care for selected retinal conditions involving abnormal blood-vessel growth. By inhibiting VEGF activity, it helps reduce the formation of new blood vessels and supports established therapeutic approaches. The product is administered according to specific clinical protocols and healthcare-professional guidance based on the intended indication.